Along this line of research, Wang et al. have shown that the combination of two Food and Drug Administration (FDA)-approved drugs entailing the proteasome inhibitor bortezomib (BTZ) and the histone deacetylase (HDAC) inhibitor vorinostat concertedly induce dramatic cell death in NB cell lines in part through synergistic activation of BAX in MYCN transformed NB cell lines [65]. The gene discussed is MYCN; the disease is neuroblastoma.